Company intelligence / Profile preview

Genticel

Labège/Toulouse, Occitanie, Francelive.euronext.com ↗

Ownership: Private
Employees: ~33
Development stage: Phase 2

Overview

Genticel developed therapeutic vaccines targeting women already infected with high-risk human papillomavirus types to prevent progression to cervical cancer. Its lead candidate, GTL001/ProCervix, reached Phase II clinical trials but failed to meet its primary endpoint mid-trial; however, subsequent results were more promising. A second-generation multivalent vaccine candidate, GTL002, achieved preclinical proof-of-concept.

Therapeutic areas: Women's Health
Modalities: VaccineProteinBiologic
Industry: Biotech

Drug pipeline

1 asset

GTL001

Phase 2

Indications: HPV infection, Cervical cancer

Beyond the preview

Go deeper on Genticel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genticel.

Explore the full profile